These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 28737768)
1. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768 [TBL] [Abstract][Full Text] [Related]
2. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333 [TBL] [Abstract][Full Text] [Related]
3. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609 [TBL] [Abstract][Full Text] [Related]
4. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer. Kim M; Lu F; Zhang Y Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437 [TBL] [Abstract][Full Text] [Related]
5. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Guan B; Wang TL; Shih IeM Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401 [TBL] [Abstract][Full Text] [Related]
6. A key HDAC6 dependency of ARID1A-mutated ovarian cancer. Altucci L Nat Cell Biol; 2017 Jul; 19(8):889-890. PubMed ID: 28752851 [TBL] [Abstract][Full Text] [Related]
7. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors. Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303 [TBL] [Abstract][Full Text] [Related]
8. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Fukumoto T; Fatkhutdinov N; Zundell JA; Tcyganov EN; Nacarelli T; Karakashev S; Wu S; Liu Q; Gabrilovich DI; Zhang R Cancer Res; 2019 Nov; 79(21):5482-5489. PubMed ID: 31311810 [No Abstract] [Full Text] [Related]
9. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712 [TBL] [Abstract][Full Text] [Related]
11. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II. Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775 [TBL] [Abstract][Full Text] [Related]
12. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Yano M; Katoh T; Miyazawa M; Miyazawa M; Ogane N; Miwa M; Hasegawa K; Narahara H; Yasuda M Sci Rep; 2019 Feb; 9(1):2397. PubMed ID: 30787326 [TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770 [TBL] [Abstract][Full Text] [Related]
17. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Meng Z; Jia LF; Gan YH Oncogene; 2016 May; 35(18):2333-44. PubMed ID: 26279303 [TBL] [Abstract][Full Text] [Related]
18. A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment. Nettersheim D; Jostes S; Fabry M; Honecker F; Schumacher V; Kirfel J; Kristiansen G; Schorle H Oncotarget; 2016 Nov; 7(46):74931-74946. PubMed ID: 27572311 [TBL] [Abstract][Full Text] [Related]
19. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Ozaki T; Wu D; Sugimoto H; Nagase H; Nakagawara A Cell Death Dis; 2013 Apr; 4(4):e610. PubMed ID: 23618908 [TBL] [Abstract][Full Text] [Related]
20. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]